TITLE

THE CLINICAL SIGNIFICANCE AND THE EXPRESSION OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN PATIENTS WITH CHRONIC HEART FAILURE

PUB. DATE
October 2010
SOURCE
Heart;Oct2010 Supplement, pA209
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
An abstract of the article "The Clinical Significance and the Expression of N-Terminal Pro-Brain Natriuretic Peptide in Patients With Chronic Heart Failure" by Qiushi Cheng, Tian Lv, Hongjiu Yu and Mei Wang is presented.
ACCESSION #
66246105

 

Related Articles

  • GPs urged to choose lab-based test to rule out heart failure. Kelly, Brian // Pulse;5/12/2003, Vol. 63 Issue 19, p10 

    Examines the effectiveness of the N-terminal pro-brain natiuretic peptide test, a blood test processed in the laboratory to rule out heart failure. Avoiding inappropriate referrals; Guidance on the test to be issued by the Great Britain National Institute for Clinical Excellence.

  • M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics. McKie, Paul M.; Cataliotti, Alessandro; Ichiki, Tomoko; Jeson Sangaralingham, S.; Horng H Chen; Burnett Jr, John C. // BMC Pharmacology & Toxicology;2013, Vol. 14 Issue Suppl 1, p1 

    An abstract of the paper "M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cyclic guanosine monophosphate activating therapeutics" presented at the 6th International Conference on cGMP held in Germany in 2013 is presented.

  • BNP monitoring plus protocol improves HF outcomes.  // JAAPA: Journal of the American Academy of Physician Assistants (;Jun2010, Vol. 23 Issue 6, p55 

    The article reports on a study which found that regular monitoring of b-type natriuretic peptide (BNP) with intensification of drug therapy as needed, results in improved survival in heart failure (HF) patients under 75 years of age.

  • Chest radiographs and BNP levels provided complementary information beyond clinical findings for diagnosing heart failure. Henriksson, Peter // Evidence Based Medicine;Sep/Oct2004, Vol. 9 Issue 5, p152 

    The article provides an answer to a question on the effectiveness of chest radiography and circulating B type natriuretic peptide (BNP) in the diagnosis of heart failure.

  • TGF-�1 and angiotensin networking in cardiac remodeling. Rosenkranz, Stephan // Cardiovascular Research;Aug2004, Vol. 63 Issue 3, p423 

    The renin�angiotensin system (RAS) and transforming growth factor-�1 (TGF-�1) play a pivotal role in the development of cardiac hypertrophy and heart failure. Recent studies indicate that angiotensin II (Ang II) and TGF-�1 do not act independently from one another but rather...

  • Fibroblast growth factor 2 isoforms and cardiac hypertrophy. Kardami, Elissavet; Jiang, Zhi-Sheng; Jimenez, Sarah K.; Hirst, Cheryl J.; Sheikh, Farah; Zahradka, Peter; Cattini, Peter A. // Cardiovascular Research;Aug2004, Vol. 63 Issue 3, p458 

    Fibroblast growth factor 2 (FGF-2), a multifunctional polypeptide that affects cell growth and differentiation and becomes upregulated by stress, is expressed as AUG-initiated 18 kDa FGF-2 or CUG-initiated 21�34 kDa (hi-FGF-2) isoforms. Animal models have provided strong evidence that FGF-2...

  • Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Hanna, Nessrine; Cardin, Sophie; Leung, Tack-Ki; Nattel, Stanley // Cardiovascular Research;Aug2004, Vol. 63 Issue 2, p236 

    Background: Congestive heart failure (CHF) causes arrhythmogenic remodeling in both atria and ventricles, but differences between atrial and ventricular remodeling in CHF have not been well characterized. Methods and results: We examined atrial and ventricular tissues from dogs with CHF induced...

  • 351 B-type natriuretic peptide can predict the medium-term risk of patients with acute heart failure and preserved systolic function.  // European Journal of Heart Failure. Supplements;Jun2005, Vol. 4 Issue 1, p77 

    An abstract of the article "B-Type Natriuretic Peptide Can Predict the Medium-Term Risk of Patients With Acute Heart Failure and Preserved Systolic Function," by N. Aspromonte and colleagues is presented.

  • Nesiritide: A Review of its Use in Acute Decompensated Heart Failure. Keating, G.M.; Goa, K.L. // Drugs;2003, Vol. 63 Issue 1, p47 

    Nesiritide (Natrecor) is a recombinant form of human B-type (brain) natriuretic peptide that has beneficial vasodilatory, natriuretic, diuretic and neurohormonal effects. The drug is administered intravenously for the management of patients with decompensated congestive heart failure (CHF). In...

  • Nesiritide and heart failure.  // Primary Care Reports;Sep2011 Supplement, p2 

    The article offers information on a study that raised questions about the safety of nesiritide which is being used in congestive heart failure.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics